UK Markets closed

e-Therapeutics plc (ETX.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
36.00+2.25 (+6.67%)
At close: 4:35PM BST

e-Therapeutics plc

17 Blenheim Office Park
Long Hanborough OX29 8LN
United Kingdom
44 1993 880 000

Full-time employees25

Key executives

NameTitlePayExercisedYear born
Mr. Ahmad Ali MortazaviCEO & Director135.89kN/A1971
Dr. Karl Keegan BSc, MPhil, Ph.D., MScChief Financial OfficerN/AN/A1967
Mr. Jonny Wray Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. Alan Whitmore B.Sc., Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Sarah ClareDirector of Fin. & ComplianceN/AN/AN/A
Ms. Stephanie Maley CIPDChief People OfficerN/AN/AN/A
Mr. Colin Stubberfield Ph.D.Chief Research OfficerN/AN/AN/A
Dr. Laura Roca-Alonso Ph.D.Chief Bus. OfficerN/AN/AN/A
Adam SardarHead of Data ScienceN/AN/AN/A
Ms. Alison GallafentHead of Intellectual PropertyN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


e-Therapeutics plc operates as a drug discovery company in the United Kingdom. The company's Network-Driven Drug Discovery platform perform in silico phenotypic screens to generate sets of small molecules that are enriched in active compounds ensuring high in vitro hit rates in complex phenotypic screens; and Genome-Associated Interaction Networks platform to analyze genome-wide association study data, which identifies disease variants at the genome level to identify potential intervention strategies, therapies, and diagnostics, as well as developing RNAi platform to modulate any gene to harness novel targets identified computationally. It also develops search engine technology. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.

Corporate governance

e-Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.